

**GOVERNMENT OF INDIA
MINISTRY OF HEALTH AND FAMILY WELFARE
DEPARTMENT OF HEALTH AND FAMILY WELFARE**

**LOK SABHA
UNSTARRED QUESTION NO. 389
TO BE ANSWERED ON 03.02.2023**

MORTALITY DUE TO SNAKE BITE

**389. SHRIMATI SHARDABEN ANILBHAI PATEL:
SHRI MITESH RAMESHBHAI PATEL (BAKABHAI):**

Will the Minister of **HEALTH AND FAMILY WELFARE** be pleased to state:

- (a) whether the World Health Organization has reported that about 58,000 people are dying due to snake bite in the country and, if so, the steps taken/ being taken by the Government to reduce such mortality rate;
- (b) whether it is a fact that about 90 percent deaths occurred due to snake bite in rural areas and, if so, the steps taken/being taken by the Government to set up medical infrastructure for the same in rural areas;
- (c) whether the existing manufacturing units are capable for producing anti-venom medicines in enough quantity to treat the patients of snake bite; and
- (d) if so, the production capacities-wise details of the companies thereof?

**ANSWER
THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND
FAMILY WELFARE
(DR. BHARATI PRAVIN PAWAR)**

(a) to (d):

As per the information received from WHO country office, India, WHO has not released any report on mortality due to snakebites.

As per information received from States/UTs, 626 deaths have been reported in year 2020.

Government of India provides financial assistance to all states under National Health Mission (NHM) for strengthening public health care system including setting up of new hospitals and infrastructure upgradation under various schemes including management of

snake bite cases. Further to ensure drugs availability, Anti-Snake Venom (ASV), has already been included in the National Essential Drug List and State Governments have also been communicated to include ASV in essential drug list.

As per approval in Mission Steering Group (MSG) of NHM, additional activities have been added for prevention and control of snake bites for implementation across all states/UTs from the financial year 2023-24. These include awareness on snake bite prevention and first aid, capacity building of frontline health workers and IEC activities.

The detail of the Manufacturers for Anti-Snake Venom Serum with installed capacity is as follows:

S. No.	Name of Manufacturer	Installed Capacity (Vials/annum)
1.	M/s Virchow Biotech Pvt. Ltd.	4,32,000
2.	M/s Haffkine Biopharmaceuticals Corporation Limited	4,50,000
3.	M/s Biological E. Limited	8,40,000
4.	M/s Premium Serums and Vaccines Pvt. Ltd.	14,40,000
5.	M/s Bharat Serums and Vaccines Limited	21,00,000
6.	M/s VINS Bioproducts Limited	13,60,000
7.	M/s Central Research Institute	10,000
8.	M/s Serum Institute of India Pvt. Ltd., Pune	1,20,000
